- Zacks•4 days ago
Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.
- Forbes•4 days ago
The year 2016 was a mixed one for Swiss pharmaceutical giant Roche . While the overall business improved on the back of the launch of new products and growth in the HER2+ drug franchise, the stock fell as investors remained cautious regarding broader industry factors. Overall, there was no change
- Bloomberg•4 days ago
Jean-Paul and Martine Clozel represent the dream of just about every pharmaceutical researcher. After the multinational that employed them declined to pursue a compound they discovered, the Clozels founded ...
RHHVF : Summary for ROCHE HLDGS AG GENUSSCHEINE NPV - Yahoo Finance
Roche Holding AG (RHHVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||220.71 - 224.05|
|52 Week Range||216.45 - 256.54|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|